Search Results
Know Your Myeloma Immunotherapy: Teclistamab and other Bispecifics
Know Your Myeloma Immunotherapy: Bispecific Antibodies with Dr. Cesar Rodriguez
Teclistamab - Guest Lecture
TECVAYLI (Teclistamab) Everything You Need to Know
Bispecific antibodies in multiple myeloma: teclistamab, talquetamab, and cevostamab
Hitting the BCMA Target in Multiple Myeloma
The Latest Insights on Immune Therapies in Myeloma | 2023 IMF Patient and Family Seminar
Safety & efficacy of bispecific antibodies in multiple myeloma: teclistamab & elranatamb
What are the differences between CAR T-cell therapy and bispecific antibodies?
FDA approval of teclistamab for R/R multiple myeloma and the value of immunotherapies
Teclistamab Approval For Multiple Myeloma Treatment | Ross Firestone, MD, PhD | ASCO 2023
Teclistamab, a BCMA × Cd3 Bispecific Antibody, in Pts with RRMM: Updated Phase 1 Results
